{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T15:14:26Z","timestamp":1760800466293,"version":"3.44.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.cpcardiol.2021.100932","type":"journal-article","created":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T06:25:45Z","timestamp":1627107945000},"page":"100932","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Hyperhomocysteinemia as a Link of Chemotherapy-Related Endothelium Impairment"],"prefix":"10.1016","volume":"47","author":[{"given":"Ashot","family":"Avagimyan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2021.100932_bib0001","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: Update from the GBD 2019 Study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0002","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1136\/jech-2020-214050","article-title":"Combined lifestyle factors, all-cause mortality, and cardiovascular disease: a systematic review and meta-analysis of prospective cohort studies","volume":"75","author":"Zhang","year":"2021","journal-title":"J Epidemiol Community Health"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0003","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11912-020-01013-7","article-title":"Chemotherapy and radiation-associated cardiac autonomic dysfunction","volume":"23","author":"Teng","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0004","doi-asserted-by":"crossref","first-page":"7698","DOI":"10.3390\/ijms21207698","article-title":"Homocysteine and mitochondria in cardiovascular and cerebrovascular systems","volume":"21","author":"Kaplan","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0005","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jacbts.2018.06.005","article-title":"Role of endothelium in doxorubicin-induced cardiomyopathy","volume":"3","author":"Luu","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0006","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41569-020-0431-7","article-title":"Ageing, and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6","volume":"18","author":"Tyrrell","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0007","doi-asserted-by":"crossref","first-page":"169","DOI":"10.15829\/1560-4071-2019-12-169-174","article-title":"The role of Helicobacter pylori in cardiovascular toxicity mechanisms","volume":"24","author":"Avagimyan","year":"2019","journal-title":"Russ J. Cardiol"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0008","first-page":"947","article-title":"The role of viral infection in the mechanisms of initiation of atherogenesis and destabilization of atheroma","volume":"11","author":"Avagimyan","year":"2019","journal-title":"Cardiol Belarus"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0009","series-title":"Curr. Probl Cardiol","article-title":"Anthracycline associated disturbances of cardiovascular homeostasis","author":"Avagimyan","year":"2021"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0010","doi-asserted-by":"crossref","first-page":"56","DOI":"10.25040\/lkv2019.04.051","article-title":"Cardiotoxicity of chemotherapeutic drugs","volume":"4","author":"Avagimyan","year":"2019","journal-title":"Lviv Clin. Bull."},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0011","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1124\/jpet.120.000323","article-title":"Predictors of early or delayed diastolic dysfunction after anthracycline-based or nonanthracycline chemotherapy: a pharmacological appraisal","volume":"376","author":"Minotti","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0012","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2018.02.005","article-title":"Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial","volume":"94","author":"Cardinale","year":"2018","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.cpcardiol.2021.100932_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00059-018-4779-y","article-title":"Preventive use of carvedilol for anthracycline-induced cardiotoxicity: a systematic review and meta-analysis of randomized controlled trials","volume":"45","author":"Zhan","year":"2020","journal-title":"Herz"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0014","doi-asserted-by":"crossref","first-page":"316","DOI":"10.18821\/0869-2106-2018-24-6-316-323","article-title":"Ability to prevent and treat the cardiovascular system damages, caused by the use of anti-cancer drugs","volume":"24","author":"Ibragimova","year":"2018","journal-title":"Med J Russ. Fed"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0015","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/ejhf.2017","article-title":"Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology","volume":"22","author":"Pudil","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0016","first-page":"119","article-title":"Chemotherapy cardiotoxicity screening with cardiac troponins","author":"Krikunova","year":"2015","journal-title":"Russ J Cardiol"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0017","first-page":"119","article-title":"\u0421hemotherapy cardiotoxicity screening with cardiac troponins","author":"Krikunova","year":"2015","journal-title":"Russ J Cardiol"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0018","series-title":"StatPearls","article-title":"Dexrazoxane","author":"Eneh","year":"2021"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0019","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ijcard.2019.07.096","article-title":"Echocardiographic long-term follow-up of adult survivors of pediatric cancer treated with Dexrazoxane-Anthracyclines association","volume":"299","author":"Filomena","year":"2020","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0020","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4143\/crt.2017.457","article-title":"Risk factor analysis for secondary malignancy in dexrazoxane-treated pediatric cancer patients","volume":"51","author":"Kim","year":"2019","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0021","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.metabol.2015.10.022","article-title":"The protective effect of trimetazidine on myocardial ischemia\/reperfusion injury through activating AMPK and ERK signaling pathway","volume":"65","author":"Liu","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0022","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijcard.2019.05.063","article-title":"Trimetazidine in cardiovascular medicine","volume":"293","author":"Marzilli","year":"2019","journal-title":"Int J Cardiol"},{"issue":"Supplement_1","key":"10.1016\/j.cpcardiol.2021.100932_bib0023","doi-asserted-by":"crossref","DOI":"10.1093\/ehjci\/jez319.1007","article-title":"P1587 Echocardiographic estimation of the impact of long-term treatment with Trimetazidine on myocardial dysfunction in patients with ST elevation myocardial infarction","volume":"21","author":"Svanidze","year":"2020","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0024","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1527-3466.1998.tb00364.x","article-title":"Trimetazidine: experimental and clinical. Update review","volume":"16","author":"Ed","year":"1998","journal-title":"Curdioiwscular Drug Rt."},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0025","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00280-019-04019-6","article-title":"Cardioprotective effects of dapsone against doxorubicin-induced cardiotoxicity in rats","volume":"85","author":"Sheibani","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0026","doi-asserted-by":"crossref","DOI":"10.1177\/2156587218757649","article-title":"Protective effect of kolaviron on cyclophosphamide-induced cardiac toxicity in rats","volume":"23","author":"Omole","year":"2018","journal-title":"J Evid Based Integr Med"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0027","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.2174\/1381612824666180625125450","article-title":"Coronary microvascular and cardiac dysfunction due to homocysteine pathometabolism; a complex therapeutic design","volume":"24","author":"Koller","year":"2018","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109859","article-title":"Homocysteine as a potential predictor of cardiovascular risk in patients with COVID-19","volume":"143","author":"Ponti","year":"2020","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0029","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/7404397","article-title":"Abnormal biomarkers of homocysteine metabolism in neonates with conotruncal heart defects","volume":"2017","author":"Surmiak","year":"2017","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0030","first-page":"3","article-title":"Modern vision about the mechanisms of atherosclerosis development","volume":"59","author":"Avagimyan","year":"2019","journal-title":"Med. Sci. Armenia"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0031","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1515\/CCLM.2005.173","article-title":"Homocysteine, and heart failure: a review of investigations from the Framingham Heart Study","volume":"43","author":"Sundstr\u00f6m","year":"2005","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0032","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.atherosclerosis.2014.06.021","article-title":"Homocysteine induces the expression of C-reactive protein via NMDAr-ROS-MAPK-NF-\u03baB signal pathway in rat vascular smooth muscle cells","volume":"236","author":"Pang","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0033","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.thromres.2009.08.015","article-title":"Role of NMDA receptor in homocysteine-induced activation of mitogen-activated protein kinase and phosphatidyl inositol 3-kinase pathways in cultured human vascular smooth muscle cells","volume":"125","author":"Doronzo","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0034","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.biochi.2020.02.012","article-title":"Mechanisms of homocysteine-induced damage to the endothelial, medial and adventitial layers of the arterial wall","volume":"173","author":"Balint","year":"2020","journal-title":"Biochimie"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0035","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1161\/01.ATV.0000189559.87328.e4","article-title":"Hyperhomocystinemia impairs endothelial function and eNOS activity via PKC activation","volume":"25","author":"Jiang","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0036","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1172\/JCI116187","article-title":"Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen","volume":"91","author":"Stamler","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0037","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1006\/bbrc.2000.3687","article-title":"Protective effect of melatonin against homocysteine-induced vasoconstriction of human umbilical artery","volume":"277","author":"Okatani","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0038","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1172\/JCI116187","article-title":"Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen","volume":"91","author":"Stamler","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0039","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1055\/s-0038-1649723","article-title":"Effects of homocysteine and related compounds on prostacyclin production by cultured human vascular endothelial cells","volume":"70","author":"Wang","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0040","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/01.ATV.20.5.1203","article-title":"Simultaneously increased TxA(2) activity in isolated arterioles and platelets of rats with hyperhomocysteinemia","volume":"20","author":"Ungvari","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0041","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2174\/157340209788166940","article-title":"Hyperhomocysteinemia and endothelial dysfunction","volume":"5","author":"Cheng","year":"2009","journal-title":"Curr Hypertens Rev"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0042","doi-asserted-by":"crossref","first-page":"H2124","DOI":"10.1152\/ajpheart.01028.2001","article-title":"Paradoxical overexpression and translocation of connexin43 in homocysteine-treated endothelial cells","volume":"282","author":"Brodsky","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0043","first-page":"41","article-title":"Hyperhomocysteinemia, intravascular hemostasis disturbances, and clinical course of myocardial infarction","volume":"2","author":"Lusov","year":"2007","journal-title":"Russ J Cardiol"},{"key":"10.1016\/j.cpcardiol.2021.100932_bib0044","doi-asserted-by":"crossref","unstructured":"Xu B, Kong X, Xu R, et al. Homocysteine and all-cause mortality in hypertensive adults without pre-existing cardiovascular conditions: Effect modification by MTHFR C677T polymorphism. Medicine (Baltimore). 2017;96:e5862. doi: https:\/\/doi.org\/10.1097\/MD.0000000000005862.","DOI":"10.1097\/MD.0000000000007120"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014628062100147X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014628062100147X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:03:33Z","timestamp":1758938613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014628062100147X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S014628062100147X"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2021.100932","relation":{},"ISSN":["0146-2806"],"issn-type":[{"type":"print","value":"0146-2806"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperhomocysteinemia as a Link of Chemotherapy-Related Endothelium Impairment","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2021.100932","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"100932"}}